Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]
Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line.
Johnson & Johnson forecast 2020 profit below Wall Street estimates and said increased competition for the company’s off-patent treatments could somewhat limit growth in the top-earning pharmaceuticals unit.
Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.
The U.S. Food and Drug Administration declined to approve Aquestive Therapeutics Inc.’s erectile dysfunction treatment tadalafil and sought additional data.
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
Europe approved a fifth copy of AbbVie’s $18-billion-a-year biologic Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.
Novartis’ generics unit won a European panel’s recommendation for its biosimilar version of AbbVie’s Humira as the Swiss drugmaker aims to take a bite out of sales of the world’s best-selling medicine.
After six months, Teva Pharmaceutical’s search ended as the company hired a new chief executive officer.